Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
38.05
-0.19 (-0.50%)
Mar 13, 2025, 4:00 PM EST - Market closed
Legend Biotech Revenue
In the year 2024, Legend Biotech had annual revenue of $627.24M with 119.97% growth. Legend Biotech had revenue of $186.52M in the quarter ending December 31, 2024, with 134.73% growth.
Revenue (ttm)
$627.24M
Revenue Growth
+119.97%
P/S Ratio
11.09
Revenue / Employee
$240,414
Employees
2,609
Market Cap
6.99B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
LEGN News
- 2 days ago - Legend Biotech Corporation (LEGN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights - GlobeNewsWire
- 2 months ago - Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4) - Seeking Alpha
- 3 months ago - Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma - GlobeNewsWire
- 3 months ago - Legend Biotech: The Story Brightens - Seeking Alpha
- 4 months ago - Legend Biotech Corporation (LEGN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition - GlobeNewsWire